Prothena is a clinical-stage neuroscience company focused on the discovery and development of novel therapies.
Prothena Corporation plc is a late-stage clinical company with expertise in protein dysregulation and a pipeline of novel investigational therapeutics with the potential to change the course of devastating rare peripheral amyloid and neurodegenerative diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 14, 2022 | Post-IPO Equity | $172.40M | — | — | — | Detail |
May 10, 2021 | Post-IPO Equity | $60M | — | — | — | Detail |
Mar 24, 2021 | Post-IPO Equity | $67.80M | — | — | — | Detail |
Mar 29, 2018 | Post-IPO Equity | $49.99M | — | — | — | Detail |
Mar 3, 2017 | Post-IPO Equity | $155.30M | — | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Sofinnova Investments | — | Post-IPO Equity |